-
.
- eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention. . . .
scott cadger, head of underwriting and claims strategy at scottish widows, said the industry needed to do more to educate the public on the merits of protection insurance. .
the comments below have not been moderated.
yet these drugs are not a "home run," says elizabeth loder, md, a professor of neurology at harvard medical school and chief of the division of headache at brigham & women's hospital. .
OFF DEAL
218 Used Today
OFF DEAL
181 Used Today
OFF DEAL
200 Used Today